Q4 2025 · 13F-HR
TPG GP A, LLCholdings as filed
Filed 2026-02-13 · accession 0001999371-26-003325
$2.69B
Reported value
10
Positions
2025-12-31
Period end
The Brief · TPG GP A, LLC · Q4 2025
AI · grounded in 13F
TPG GP A, LLC established a new position in BETA Technologies Inc BETA, investing $462.5M. This addition represents the fund's only change to its portfolio this quarter. The fund now manages 10 positions with total assets under management of $2.69B.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 53228F101 | LFST | LifeStance Health Group Inc | $1.13B | 42.1% | 160,711,618 | Common | SOLE |
| 53190C102 | LTH | Life Time Group Holdings Inc | $473.9M | 17.6% | 17,830,652 | Common | SOLE |
| 086921103 | BETA | BETA Technologies Inc | $462.5M | 17.2% | 16,395,435 | Common | SOLE |
| 829401108 | SION | Sionna Therapeutics Inc | $277.5M | 10.3% | 6,744,962 | Common | SOLE |
| 03168L105 | AMRX | Amneal Pharmaceuticals Inc | $155.3M | 5.78% | 12,328,767 | Common | SOLE |
| 15678C102 | CBLL | CeriBell Inc. | $87.0M | 3.24% | 3,967,422 | Common | SOLE |
| 055477103 | BCAX | Bicara Therapeutics Inc. | $50.7M | 1.89% | 3,010,425 | Common | SOLE |
| 019770106 | ALLO | Allogene Therapeutics Inc | $25.6M | 0.95% | 18,716,306 | Common | SOLE |
| 87266M107 | TRTX | TPG RE Fin Tr Inc | $20.6M | 0.77% | 2,392,863 | Common | SOLE |
| 75120L100 | RLYB | Rallybio Corp | $2.1M | 0.08% | 3,028,414 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.